mingwan0.....appears dnap is following the plan that has been talked about in the TWST article.
One example....Tony telling us they would do 3 or 4 clinical trials to show what their platform can do....and then pull it away from them. The (4) four mentioned with Moffitt.
Another example....aquiring a company with drugs already in the pipeline.
We received $1,230,000 in proceeds during the first quarter of 2004 and incurred $73,425 in associated stock issuance costs and fees. During the quarter, we used approximately $637,000 of the total net proceeds for working capital, including payroll of approximately $133,500,lease and note repayments of approximately $77,000, and miscellaneous monthly payments to our vendors for materials and supplies of approximately $422,600. We also purchased laboratory equipment for approximately $3,900, leaving a cumulative balance of the net proceeds of the offering of approximately $575,400. Cumulative use of proceeds is approximately $954,700 comprised of payroll of approximately $182,500, lease and note repayments of approximately $85,700, working capital of approximately $682,600 and equipment purchases of approximately $3,900. We intend to use the remaining net proceeds from the offering for the purchase of capital equipment and for working capital. In addition, we may use a portion of the proceeds to fund acquisitions or lease real property.
Both items were mentioned in the TWST article and seem to still be part of the plan.
Knowing this....can we guess on a time frame?
We intend to use the remaining net proceeds from the offering for the purchase of capital equipment and for working capital. In addition, we may use a portion of the proceeds to fund acquisitions or lease real property.
Just guessing here. Thoughts?
IFIDA
News 
Market Data 
Discover 
